Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib plus Bevacizumab in EGFR Uncommon Mutation NSCLC
NCT05267288Phase 2Unknown
- Sponsor
- Affiliated Qingdao Central Hospital of Qingdao University
- Start
- Feb 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of afatinib, bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Affiliated Qingdao Central Hospital of Qingdao University. Status: unknown.
02
Drugs
afatinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05267288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05267288.